Multiple Sclerosis
Safety of natalizumab therapy for multiple sclerosis is focus of review
Published in Medical Letter on the CDC and FDA, October 15th, 2006
According to that review, "Multiple sclerosis affects many people, often in early adulthood, and causes significant disability. Natalizumab is a novel agent to be evaluated for multiple sclerosis and Crohn disease that has demonstrated unique efficacy but has unfortunately been implicated in three cases of progressive multifocal leukoencephalopathy."
"This review covers the mechanism of action of natalizumab and efficacy for multiple sclerosis, the three cases of natalizumab-associated progressive multifocal...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Drug Safety
U.S. FDA asks U.S. marshals to seize dietary supplements - Ophthalmology
Outbreak of Fusarium keratitis was linked to contact lens solution - Rabies Virus
New phylogenetic lineage of rabies virus is linked to western Pipistrelle bats - Vaccine Safety
Corticosteroids may reduce mortality in yellow fever vaccine-associated viscerotropic disease - Virology
Phylogenetic relationships of unclassified Rhabdoviridae viruses are reported - Acute Bacterial Sinusitis
Oscient announces results of advisory committee meeting for Factive for acute bacterial sinusitis - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
